Brief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
18/09/2026 14:16
BRIEF-Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development Sept 18 (Reuters) - Ryvu Therapeutics SA RVU.WA:
SIGNS GRANT AGREEMENT FOR PANACEA-NOVO PROJECT WITH THE NATIONAL CENTER FOR RESEARCH AND DEVELOPMENT
NET VALUE OF PROJECT AT 133.2 MILLION ZLOTYS WITH RECOMMENDED GRANT VALUE OF 105.6 MILLION ZLOTYS
PLANNED IMPLEMENTATION PERIOD FOR PROJECT IS 58 MONTHS
GOAL OF PANACEA-NOVO PROJECT IS INNOVATIVE THERAPIES FOR TREATMENT OF RARE TUMORS AMONG PATIENTS
Source text: ID:nEM7L6TPya
Further company coverage: RVU.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys